ISIS Pharmaceuticals, Inc. Share Price Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 7.63B 6.73B 6.37B 5.77B 10.83B 732B 10.93B 76.39B 29.44B 374B 28.64B 28.01B 1,203B | P/E 2026 * |
-12.8x | P/E 2027 * | -23.5x |
|---|---|---|---|---|---|
| Enterprise Value | 7.52B 6.64B 6.28B 5.7B 10.68B 722B 10.79B 75.36B 29.04B 369B 28.25B 27.64B 1,186B | EV / Sales 2026 * |
8.18x | EV / Sales 2027 * | 5.64x |
| Free-Float |
99.05% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 30/06/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 31/12/2019 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 30/04/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 12/12/2005 |
| Director/Board Member | 73 | 30/04/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 24/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 7.63B | |
| -0.36% | +3.67% | +10.47% | +38.50% | 48.85B | |
| -0.73% | -0.41% | +48.84% | +36.72% | 44.28B | |
| +1.36% | +6.03% | +343.85% | +638.73% | 43.83B | |
| -0.47% | -0.76% | +9.75% | +103.07% | 41.53B | |
| +0.34% | +0.22% | +5.18% | +47.36% | 30.13B | |
| +1.00% | -1.28% | +24.23% | +156.93% | 17.36B | |
| -0.87% | -0.74% | +22.37% | +44.44% | 14.99B | |
| -2.94% | +6.98% | +5.10% | - | 14.9B | |
| -0.86% | -4.00% | - | - | 14.98B | |
| Average | +0.07% | +0.61% | +58.72% | +152.25% | 30.09B | |
| Weighted average by Cap. | +0.00% | +1.21% | +74.79% | +168.48% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 920M 811M 768M 696M 1.31B 88.24B 1.32B 9.21B 3.55B 45.06B 3.45B 3.38B 145B | 1.36B 1.2B 1.14B 1.03B 1.94B 131B 1.96B 13.67B 5.27B 66.87B 5.12B 5.01B 215B |
| Net income | -576M -509M -481M -436M -818M -55.29B -826M -5.77B -2.22B -28.24B -2.16B -2.12B -90.86B | -330M -291M -276M -250M -469M -31.68B -473M -3.31B -1.27B -16.18B -1.24B -1.21B -52.06B |
| Net Debt | -103M -90.89M -85.99M -77.99M -146M -9.88B -148M -1.03B -398M -5.05B -387M -378M -16.24B | 68.31M 60.28M 57.04M 51.73M 96.98M 6.55B 97.93M 684M 264M 3.35B 256M 251M 10.77B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
